-
SARS-CoV-2 N Protein Phase Separation and GCG
2026-08-25
The reference study identifies RNA-triggered liquid–liquid phase separation of the SARS-CoV-2 nucleocapsid protein as a mechanistic step in viral organization and replication. It further links the prevalent R203K/G204R N-protein variant to enhanced condensation and shows that gallocatechin gallate can disrupt this process in experimental systems, while leaving important questions about specificity and clinical translation.
-
FK866 (APO866): NAMPT Inhibition in Cancer Research
2026-08-24
FK866, also called APO866, is a non-competitive NAMPT inhibitor that lowers intracellular NAD and ATP. Its strongest research use is mechanistic study of NAD metabolism, hematologic cancer biology, and combination strategies that exploit metabolic stress.
-
Nigericin Sodium Salt for Cell Assay Workflows
2026-08-24
Nigericin sodium salt is a potassium ionophore for controlled K+/H+ exchange, rapid cytoplasmic pH perturbation, and ion-sensitive cell assays. This guide translates those properties into practical workflows for platelet studies, lead-ion transport experiments, and more discriminating cancer drug-response measurements.
-
Isoprenaline Hydrochloride: Designing Better Assays
2026-08-23
Isoprenaline Hydrochloride, also known as isoproterenol, is more than a β-adrenergic stimulant: it is a controllable perturbation for separating cardiac, neural, and vascular readouts. This guide translates heart–brain axis findings into rigorous assay-design decisions for cardiovascular and translational research.
-
SP2509: Lysine-Specific Demethylase 1 Antagonist
2026-08-22
SP2509 is a selective LSD1 antagonist for connecting biochemical inhibition with H3K4 methylation, transcriptional reactivation, apoptosis induction in AML cells, and differentiation phenotypes. This workflow-oriented guide explains formulation, assay design, combination testing, and troubleshooting while distinguishing AML evidence from insights derived from broader cancer epigenetics research.
-
FK866 (APO866): Reliable NAMPT Assays
2026-08-22
Learn how FK866 (APO866), SKU A4381, can improve the interpretation and reproducibility of NAMPT inhibition experiments in AML and broader hematologic cancer research. This scenario-based guide covers assay design, formulation, mechanism-aware controls, data interpretation, and practical product selection.
-
Novel PDK4 Inhibitors for Metabolic Disease Research
2026-08-21
The 2019 Journal of Medicinal Chemistry study identified compound 8c as a potent allosteric pyruvate dehydrogenase kinase 4 inhibitor derived from an anthraquinone hit. Its biochemical activity, drug-like disposition, glucose-tolerance effects, antiallergic activity, and anticancer signals establish a useful preclinical framework while leaving important questions about selectivity, exposure, safety, and clinical translation.
-
AO/PI Double Staining Kit for Cell Fate
2026-08-20
Turn one rapid fluorescent readout into a practical map of viable, apoptotic, and membrane-compromised cells. This AO/PI workflow supports routine cell viability assay QC, cytotoxicity screening, organoid studies, and post-enrichment assessment of rare circulating cells.
-
RSL3: A GPX4 Inhibitor for Ferroptosis Assays
2026-08-20
RSL3 is a glutathione peroxidase 4 inhibitor that converts hidden redox vulnerability into measurable ferroptosis. This article presents an assay-centered framework linking GPX4 inhibition with lipid peroxidation, inflammatory signaling, oncogenic RAS synthetic lethality, and cross-domain research applications.
-
Anti Reverse Cap Analog: B8175 Guide
2026-08-19
A scenario-based guide to using Anti Reverse Cap Analog (ARCA), 3´-O-Me-m7G(5')ppp(5')G (SKU B8175) when synthetic mRNA expression affects viability, proliferation, or cytotoxicity assays. It connects cap orientation, in vitro transcription parameters, assay controls, interpretation limits, and practical product-selection criteria.
-
Lovastatin Workflows for Mechanistic Cell Research
2026-08-19
Lovastatin enables more than cholesterol-pathway inhibition: it supports structured studies of proliferation, apoptosis, fibroblast responses, macrophage efferocytosis, and cancer-cell phenotypes. This practical guide connects dose design, pathway-aware readouts, and the KNUCKLES floral-meristem study’s logic for separating molecular events from downstream outcomes.
-
ARCA for High-Efficiency Synthetic mRNA Capping
2026-08-18
Anti Reverse Cap Analog (ARCA), 3´-O-Me-m7G(5')ppp(5')G, is an orientation-selective Cap 0 analog for in vitro transcription. Product information reports approximately twofold higher translation than conventional m7G cap analogs under its stated comparison, while the supplied dossier recommends a 4:1 ARCA-to-GTP molar ratio for approximately 80% capping efficiency.
-
Cyclophosphamide: Mechanism and Research Workflow
2026-08-18
Cyclophosphamide is an alkylating chemotherapeutic agent that requires hepatic bioactivation before producing DNA cross-linking cytotoxicity. Its product specifications support controlled cancer research, apoptosis induction in cancer cells, immune-regulation studies, and bone marrow transplantation conditioning workflows.
-
Anti Reverse Cap Analog for Cell Reprogramming
2026-08-17
Anti Reverse Cap Analog, 3´-O-Me-m7G(5')ppp(5')G, improves the orientation and functional quality of capped synthetic mRNA. This article connects cap chemistry with assay design for transient OLIG2-driven cell reprogramming, highlighting practical controls and evidence-based limitations.
-
ZK53: Human ClpP Activator Workflows
2026-08-17
ZK53 is a selective human mitochondrial serine protease ClpP activator for connecting mitochondrial proteostasis, oxidative phosphorylation failure, DNA damage signaling, and ferroptosis sensitivity in cancer models. This workflow-focused guide shows how to choose assay formats, build concentration ranges, validate mechanism, and troubleshoot discordant biochemical and cellular results.